1632



Att'y Dkt. No. 4001-0003CIP U.S. App. No. 09/843,922

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Fukumura et al. Art Unit: 1632

Appl. No.: 09/843,922 Examiner: Baker, A.

Filing Date: April 1, 2001 Atty. Docket: 4001-0003CIP

Title: Negative-Sense RNA Virus Vector For Nerve

Cell

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on the accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that an exhaustive search has been made, or that there does not exist information more material to the examination of the present patent application. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will review art of record in all 35 U.S.C. § 120 priority documents.

1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

⊠2. The Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
⊠b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56 (c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
c. Attached is our check no in the amount of \$ in payment of the fee under 37 C.F.R. § 1.17(p).
☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicants hereby petition that the Information Disclosure Statement be considered. Attached is our check no in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).
a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
b. I hereby certify that no item of information on this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
A. Relevance of the non-English language document(s) is discussed in the present specification. See of the specification of the present application.
∑5. The document(s) was/were cited in a corresponding foreign application. ☐ A copy of a search report issued in the foreign application is attached. ☐ An English language version of the foreign search report is attached for the Examiner's information. M.P.E.P. § 609 (A)(3).
⊠6. A concise explanation of the relevance of the non-English language document(s) ⊠ is attached hereto or ☐ appears below.

Att'y Dkt. No. 4001-0003CIP U.S. App. No. 09/843,922

□ 7.	The Examiner's attention is directed to co-pending U.S. Patent Application No, filed, which is directed to related technical subject matter. The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to that application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.							
□8.	Copies of the documents were cited by or submitted to the Office in Application No, filed, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).							
9 .	Other: .							
	It is respectfully requested that the Examiner in	tial and re	eturn a copy of the enclosed PTO-1449,					
and to i	indicate in the official file wrapper of this patent	application	n that the documents have been					
considered.								
	The Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment,							
to our Deposit Account No. 50-0622								
		Respectfu	ully submitted,					
		SHANKS	S & HERBERT					
		ву:						
Date:	8/28/03	R	Reg. No. 33,781					

TransPotomac Plaza 1033 N. Fairfax Street Suite 306 Alexandria, VA 22314 703-683-3600

	FORM PTO 1449				ATTY. DOCKET NO. APPLICATION NO.						
100	O INFORMATION DISCLOSURE STATEMENT				4001-0003CIP			09/843,922			
10 WF 6	MITION	N DISC	CLOSURE STATE	MENT	APPLICANT(S)						
	3				Fukumura et al.						
2 2 20	B -1				FILING DATE GROUP						
AUG Z G Z	AUG 2 8 2003					April 30, 2001			1632		
<u> </u>	. 8/			U.S. P.	PATENT DOCUMENTS						
TANKA P	•	DO	CUMENT	DATE	NAME		CLASS	SUB-CLASS	FILING DATE		
NITALE	1		MBER								
	AA1	1						1 -			
	AB1			 				 			
	AC1	<u> </u>		 							
	AD1			 							
-	AE1	1		<u> </u>							
· · · · · · · · · · · · · · · · · · ·	AF1	+				·					
	AG1	 		-							
-	AH1			 					- 		
 	AII	 									
	AJ1	+		+							
	AK1	\vdash		 	+						
	AKI	1	 	EODEICE	I N PATENT DOCU	IMENITS		<u>.ł.</u>	1		
	1	I DO	CUMENT	DATE	COUNTRY		CLASS	SUB-	TRANSLATION		
EXAMINER INITIAL			MBER	DATE	COUNTRI	'	CLASS	CLASS	IRANSLATION		
	AL1	NO	WIDER	- 				CLASS	□Yes		
	ALI								□ No		
	AM1	┼	 		 				□Yes		
	AMI	1							□ No		
	AN1	<u> </u>			 			· · · · · · · · · · · · · · · · · · ·	□Yes		
	ANI								□ No		
	AO1	+-		***					□Yes		
1	AOI										
	AP1	 			 				□Yes		
	API										
	1		OTHER (Including A	uthor, Title, Date,	Portingnt	Dagge of	1			
	1	1	OTHER (meruumg A	Effects of Endoses	reruneni	tu Subata	noos on Proin "	Inst. Of Bio-Active		
		ŀ	Comura, Y., Ph	ysiologicai i Zoki Dhorm	enects of Endoger	10us Saut	75 (with I	inces on Brain, English evaluant	inst. Of Bio-Active		
	Science, Nippon Zoki Pharmaceutical (1998); 20: 567-575 (with English explanation of the AR 1								1011).		
	AK	-	$\frac{1}{2}$								
		+			 						
	AS	1									
		-									
	1	†							<u> </u>		
	AT	1									
		-									
		1									
EXAMINER DATE CONSIDERED											
EXAMIN	IER: Initi	al if re	ference considered	, whether or	not citation is in	conforma	nce with l	MPEP 609. Dra	w line through		

citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.